Recovering Abandoned Compounds Through Expanded External IP Licensing Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

Pharmaceutical drug development prices have risen quickly over the past twenty years. The amount of new molecular entities being approved has not escalated.

Many of these prices may be traced to work on compounds which are abandoned before getting to market. As pharmaceutical companies scale back their work in light of deteriorating R&D productivity, major unmet medical needs remain unaddressed.

More extensive outside licensing of the IP associated with compounds that are deserted could spur restoration or redeployment of forgotten compounds to deal nevertheless some of these unmet medical needs. The illustration of Cubicin is providing as an instance of these more strategies that were open. This post inductively develops a straightforward framework to direct companies in the decision of when and whether to license out internal IP that is unused.

Recovering Abandoned Compounds Through Expanded External IP Licensing Case Study Solution

PUBLICATION DATE: August 01, 2013 PRODUCT #: CMR546-HCB-ENG

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE